Asset profile

vedolizumab · Entyvio

Monoclonal antibody

Approvedregulatory verdict

Evidence outlook

Approved — Crohn's Disease, Ulcerative Colitis

Regulatory approval supersedes design-level evidence grading — the trials behind approval are preserved below as the drug's evidence history.

track record: Reliable signal

How the evidence outlook works ↗

Upcoming events

(12 total)

Estimated primary-completion dates from ClinicalTrials.gov — registry estimates, never confirmed readout dates; they can move as trials progress.

2027 (5)
June 2027 (1)
Phase 3Crohn's DiseaseRecruiting
Est. primary completion 2027-06-08 · NCT06227910 · CT.gov ↗
What to watch

Research analysis

Source-grounded endpoint goals, benchmarks, comparator context, and caveats for this readout are included with Research.

August 2027 (1)
Phase 3Ulcerative ColitisActive not recruiting
Est. primary completion 2027-08 · NCT06880744 · CT.gov ↗
What to watch

Research analysis

Source-grounded endpoint goals, benchmarks, comparator context, and caveats for this readout are included with Research.

September 2027 (2)
Phase 3Crohn's DiseaseRecruiting
Est. primary completion 2027-09-13 · NCT04779320 · CT.gov ↗
What to watch

Research analysis

Source-grounded endpoint goals, benchmarks, comparator context, and caveats for this readout are included with Research.

Phase 3Ulcerative ColitisActive not recruiting
Est. primary completion 2027-09-24 · NCT03221036 · CT.gov ↗
What to watch

Research analysis

Source-grounded endpoint goals, benchmarks, comparator context, and caveats for this readout are included with Research.

December 2027 (1)
Phase 1/2Colitis, Lung Non-Small Cell Carcinoma, Malignant Genitourinary System Neoplasm, Malignant Solid Neoplasm, MelanomaActive not recruiting
Est. primary completion 2027-12-31 · NCT04407247 · CT.gov ↗
What to watch

Research analysis

Source-grounded endpoint goals, benchmarks, comparator context, and caveats for this readout are included with Research.

2028 (4)
April 2028 (1)
Phase 3Ulcerative ColitisNot yet recruiting
Est. primary completion 2028-04-30 · NCT06614387 · CT.gov ↗
What to watch

Research analysis

Source-grounded endpoint goals, benchmarks, comparator context, and caveats for this readout are included with Research.

May 2028 (1)
Phase 3Crohn's DiseaseRecruiting
Est. primary completion 2028-05-16 · NCT06100289 · CT.gov ↗
What to watch

Research analysis

Source-grounded endpoint goals, benchmarks, comparator context, and caveats for this readout are included with Research.

October 2028 (2)
Phase 2Crohn's DiseaseRecruiting
Est. primary completion 2028-10 · NCT03219359 · CT.gov ↗
What to watch

Research analysis

Source-grounded endpoint goals, benchmarks, comparator context, and caveats for this readout are included with Research.

Phase 2Acute Lymphoblastic Leukemia, Acute Myeloid Leukemia, Chronic Myelomonocytic Leukemia, Graft Versus Host Disease, Myelodysplastic Syndrome …Recruiting
Est. primary completion 2028-10-15 · NCT06815003 · CT.gov ↗
What to watch

Research analysis

Source-grounded endpoint goals, benchmarks, comparator context, and caveats for this readout are included with Research.

2030 (2)
March 2030 (1)
Phase 3Crohn's DiseaseRecruiting
Est. primary completion 2030-03-08 · NCT05837897 · CT.gov ↗
What to watch

Research analysis

Source-grounded endpoint goals, benchmarks, comparator context, and caveats for this readout are included with Research.

August 2030 (1)
Phase 3Crohn's DiseaseRecruiting
Est. primary completion 2030-08-12 · NCT06405087 · CT.gov ↗
What to watch

Research analysis

Source-grounded endpoint goals, benchmarks, comparator context, and caveats for this readout are included with Research.

2033 (1)
February 2033 (1)
Phase 3Crohn's DiseaseRecruiting
Est. primary completion 2033-02-07 · NCT05442567 · CT.gov ↗
What to watch

Research analysis

Source-grounded endpoint goals, benchmarks, comparator context, and caveats for this readout are included with Research.

See the full readout calendar ↗

All registered studies

Research

Unlock the complete ClinicalTrials.gov registry

Research includes every linked study, indication filters, phase grouping and featured-trial cross-links.

Competitive landscape

Research

Unlock the competitor landscape

Research compares assets by shared mechanism and indication, including each competitor's stage in the relevant market.